Lapi Group at University of Alabama at Birmingham

Recent publications (last 2 years from a total of 64)
  1. Bandara, N., Cherkuri, K., Zheleznyak, A., Griffith, D.A., Limberakis, C., Tess, D.A., Chen, J., Waterhouse, R., Lapi, S.E. (2016) Evaluation of 64Cu and 68Ga Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β-cell Imaging. Molecular Imaging and Biology, 18(1) 90-8
  2. Wright, B.D., Whittenberg, J., Desai, A., DiFelice, C., Kenis, P.J.A, Lapi, S.E., Reichert, D. (2016) Microfluidic Preparation of an 89Zr-Labeled Trastuzumab Single Patient Dose. Journal of Nuclear Medicine, 57 (5) 747-52
  3. Lange, S.E.S., Zheleznyak A., Studer, M.,, O’Shannessy D.J., Lapi S.E., Van Tine B.A. (2016) Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET Applications. Oncotarget, 7 (11) 13082-92
  4. Wooten, A.L., Lewis, B.C., Szatkowski, D.J., Sultan D.H., Abdin, K.I., Voller, T.F., Liu, Y., Lapi, S.E. (2016) Calibration setting numbers for dose calibrators for the PET isotopes (52)Mn, (64)Cu, (76)Br, (86)Y, (89)Zr, (124)I. Applied Radiation and Isotopes, 113:89-95
  5. Gordon L, Lapi S.E., Anderson C, Schwarz SW; SNMMI Committee on Women in Nuclear Medicine.(2016) Working Together to Advance Women in Nuclear Medicine. Journal of Nuclear Medicine, 2016 Sep;57(9):14N
  6. Graaf MD, Marquez BV, Yeh NH, Lapi S.E., Moeller KD.(2016) New Methods for the Site-Selective Placement of Peptides on a Microelectrode Array: Probing VEGF-v107 Binding as Proof of Concept. ACS Chemical Biology, (10):2829-2837.
  7. Nie X, Randolph GJ, Elvington A, Bandara N, Zheleznyak A, Gropler RJ, Woodard PK, Lapi S.E. (2016) Imaging of Hypoxia in Mouse Atherosclerotic Plaques with (64)Cu-ATSM. Nuclear Medicine and Biology, 2016 Sep;43(9):534-42.
  8. Jin, H., Yang, H., Zhang, Y.,Zhange, X., Rosenberg, A.J., Liu, Y., Lapi, S.E., Tu, Z. (2016) A promising carbon-11-labeled sphingosine-1-phosphate receptor 1-specific PET tracer for imaging vascular injury. Journal of Nuclear Cardiology, 2016 Feb 2.
  9. Laforest, R., Lapi, S.E., Oyama, R., Bose, R.,Tabchy, A., Marquez-Nostra, B.V., Burkemper, J., Wright, B.D., Frye, J., Frye, S. Siegel, B.A., Dehdashti, F. (2016) [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging and Biology, 18(6):952-959.
  10. Nie X., Laforest R., Elvington A., Randolph GJ., Zheng J., Voller T., Abendschein DR., Lapi S.E., Woodard PK.(2016) PET/MR imaging of hypoxic atherosclerosis using 64Cu-ATSM in a rabbit model. Journal of Nuclear Medicine, 2016 Jul 7. pii: jnumed.116.172544.
  11. Burkemper JL, Aweda,TA, Rosenberg AJ, Lunderberg DL, Peaslee GF, Lapi S.E. (2017) Radiosynthesis and biological distribution of [18F]-labeled perfluorinated alkyl substances. Environmental Science and Technology Letters, DOI:10.1021/acs.estlett.7b00042
  12. Wooten AL, Aweda TA, Lewis BC, Gross RB, Lapi S.E.(2017) Biodistribution and PET Imaging of pharmacokinetics of manganese in mice using Manganese-52. PLoS One, 2017 Mar; 12(3):e0174351.doi:10.137
  13. Queern, SL, Aweda TA, Massicano AV, Clanton, NA, El Sayed, R, Sader, JA, Lapi, S.E. (2017) Production of Zr-89 using sputtered yttrium coin targets. Nuclear Medicine and Biology, 2017 Mar 23;50:11-16. doi: 10.1016.
  14. Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, Ma CX, Lapi SE. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. Oncotarget. 2017 Nov 1;8(61):104303-104314.doi: 10.18632.
  15. Radka, C. D., Radford, L. L., Massicano, A. V., DeLucas, L. J., Lapi, S. E., Aller, S. G. (2018) Essential Metal Uptake in Gram-negative Bacteria: X-ray Fluorescence, Radioisotopes, and Cell Fractionation. J. Vis. Exp. (132), e57169, doi:10.3791/57169 (2018).
  16. Massicano, A.V., Marquez-Nostra, B.V., Lapi, S.E. (2018) Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging. 2018 January. PMCID: PMC5784567.